Pfizer Stock News

"Bizarro World": Researcher Calls Out Censorship After Journal Pulls COVID-19 Vaccine Adverse Events Analysis Authored by Petr Svab via The Epoch Times (emphasis ours), Jessica Rose didnt ask for any of this. She started to analyze data on adverse reactions after COVID-19 vaccines simply as an exercise to master a new piece of software. But she couldnt ignore what she saw and decided to publish the results of her analysis. The next thing she knew, she was in a bizzarro world, she told The Epoch Times. An investigational pharmacy technician holds a dose of the Johnson & Johnson COVID-19 vaccine before it is administered in a clinical trial in Aurora, Colorado, on Dec. 15, 2020. (Michael Ciaglo/Getty Images) A paper she co-authored based on her analysis was withdrawn by the academic journal Elsevier under circumstances that raised eyebrows among her colleagues. The journal declined to comment on the matter. Rose received her PhD in computational biology from the Bar-Ilan University in Israel.

The joint Russian-Italian study was conducted by scientists from the Spallanzani Institute in Italy and Gamaleya Institute in Moscow, which developed the Sputnik V vaccine.

White House advisor Anthony Fauci said U.S. officials could authorize Pfizer and BioNTech''s Covid vaccine for children younger than 5 next month.

According to a small preliminary laboratory study, omicron-neutralizing antibodies in people vaccinated with Russia''s Sputnik V vaccine did not decline as much as of those after Pfizer Inc (NYSE: PFE ) COVID-19 shots. The joint Russian-Italian study was funded by the Russian Direct Investment Fund , which markets Sputnik V abroad. The study compared the blood serum of people who had received the different vaccines taken three to six Full story available on Benzinga.com

The study was conducted in the equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V vaccine and Pfizer

President Bidens chief medical advisor Dr. Anthony Fauci said on Wednesday that the FDA could authorize the Pfizer (PFE)/ BioNTech (BNTX) COVID-19 vaccine next month for children under

South African Scientists Confirm Boosters Offer Little Protection From Omicron On Monday, a team of Israeli scientists publicized research showing that even a second booster dose of the Moderna or Pfizer mRNA vaccines doesn''t bestow complete immunity from the omicron variant. Now, just days later, their conclusion appears to have been corroborated by a team of South African researchers from the University of Cape Town and Stellenbosch University who observed seven individuals who had been infected with the omicron variant despite having been "boosted". The patients represented the first known cases of breakthrough infection by omicron, the researchers told the Lancet , the British medical journal where their findings were published. Keep in mind, the South African team used a very different approach. First of all, the patients they examined had only received a single booster dose (unlike with the Israeli study, which focused on patients who had received two doses). As for the study''s subjects, all of them were white, and four were participating in medical training at Cape Town hospitals.

Children under 5 are the only age group who are not yet eligible to receive a COVID-19 vaccine.

Fauci said younger children will likely need three doses, because two shots did not induce an adequate immune response in children 2- to 4-years-old.

ESSA Pharma (EPIX) said the first patient was dosed in a phase 1/2 study of its lead product candidate EPI-7386, in combination with Astellas Pharma''s (ALPMF) and Pfizer''s…

NEW YORK , Jan. 19, 2022 /PRNewswire/ -- The number of people infected by the Omicron variant of COVID-19 has broken records since the new year had started. As a result of the new wave, testing kits are in short supply. According to Anthony S. Fauci , Chief Medical Adviser to President Biden, it is going to be very important "that we get a greater capability of testing, particularly when the demand for testing is so high, with the combination of the Omicron variant itself, as well as the holiday season, where people want to get that extra level of assuredness that they''re protected, even if you are vaccinated and boosted." This week, the government responded by launching a website where Americans can request a free, at-home COVID-19 test. Todos Medical Ltd. (OTC: TOMDF ), Moderna, Inc. (NASDAQ: MRNA ), Pfizer Inc. (NYSE: PFE ), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Vaxart, Inc. (NASDAQ: VXRT ) In the meantime, in New York , which is once again the epicenter of the pandemic in the U.S., it was announced that city officials are negotiating a temporary return to remote learning for tens of thousands of students who aren''t showing up for class. "The real analysis that shows we were on the right path.

ESSA Pharma Inc. (NASDAQ: EPIX ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA''s lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas Pharma Inc.''s ("Astellas") and Pfizer Inc.''s ligand-binding domain androgen receptor inhibitor, enzalutamide, in patients with metastatic castration-resistant prostate cancer ("mCRPC"). "The initiation of this combination trial with Astellas is a watershed moment for ESSA as we investigate the potential clinical benefit of inhibiting the androgen receptor through two independent pathways in the Full story available on Benzinga.com

Hyderabad: Biophore India Pharmaceuticals on Wednesday announced that it developed and started manufacturing the key intermediates of Nirmatrelvir, one of the active ingredients of Paxlovid, the latest anti-Covid therapy, approved by US authorities. The anti-viral pill developed by Pfizer recently received emergency use authorisation by the US Food and Drug Administration (USFDA). Hyderabad-based Biophore said the Get the latest updates in Hyderabad City News , Technology , Entertainment , Sports , Politics and Top Stories on WhatsApp & Telegram by subscribing to our channels. You can also download our app for Android and iOS .

GOP lawmakers on Tuesday asked the Food and Drug Administration (FDA) for answers as to why the top agency did not rely on its typical committee approval process before authorizing a third Pfizer COVID shot for children ages 12-15.